Urinary biomarkers of single oral exposures to fatty acid esters of glycidol and 2-/3-MCPD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00013219

Enrollment

Registered

2017-10-25

Start date

2017-10-23

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy participants

Interventions

Group 1: Palm fat with high content of glycidyl fatty acid esters, single consumption Group 2: Hazelnut oil with high content of 2-/3-MCPD fatty acid esters, single consumption

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: healthy non-smokers

Exclusion criteria

Exclusion criteria: - Patients with disorders associated with impaired fat absorption, impaired renal function or bladder dysfunction. - Pregnant and lactating women - Cigarette smoking - hazelnut allergy or intolerance

Design outcomes

Primary

Measure	Time frame
Increase of biomarkers 2,3-Dihydroxypropyl mercapturic acid (DHPMA) und 2-/3-monochloropropandiol (2-/3-MCPD) in urine following consumption of the study fats. Urine is collected quantitatively during the 2 days before and after exposure. The analyis is carried out by gas chromatography-mass spectrometry (GC-MS) or by high-pressure liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), respectively.	—

Measure

Time frame

Increase of biomarkers 2,3-Dihydroxypropyl mercapturic acid (DHPMA) und 2-/3-monochloropropandiol (2-/3-MCPD) in urine following consumption of the study fats. Urine is collected quantitatively during the 2 days before and after exposure. The analyis is carried out by gas chromatography-mass spectrometry (GC-MS) or by high-pressure liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), respectively.

—

Secondary

Measure	Time frame
Measurement of basal excretion of biomarkers without intervention	—

Countries

Germany

Contacts

Public ContactKlaus Abraham

Bundesinstitut für Risikobewertung

klaus.abraham@bfr.bund.de030184123369

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026